Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Birabresib + Rucaparib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Birabresib||Y-803|MK-8628|OTX015|OTX-015||BET Inhibitor (Pan) 30||Birabresib (OTX015) is an inhibitor of the BET bromodomain proteins BRD3, BRD4, and BRD5, which inhibits interaction with acetylated histone H4, potentially resulting in decreased tumor cell proliferation (Mol Cancer Ther Nov 2013 12:C244, PMID: 29733771, PMID: 31204545).|
|Rucaparib||Rubraca||AG014699|PF-01367338|CO-388|AG14447||PARP Inhibitor (Pan) 22||Rubraca (rucaparib) binds to and inhibits PARP, which may result in accumulation of DNA damage and chemosensitization of tumor cells (PMID: 17363489). Rubraca (rucaparib) is FDA approved for use as a maintenance therapy in patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, for treatment in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer harboring deleterious somatic and/or germline BRCA mutations who received 2 or more chemotherapies, and in patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer who received anti-androgen therapy and a taxane-based therapy (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||ovarian cancer||not applicable||Birabresib + Rucaparib||Preclinical - Cell culture||Actionable||In a preclinical study, the combination of Birabresib (OTX015) and Rubraca (rucaparib) resulted in a synergistic effect, demonstrating greater growth inhibition of ovarian cancer cells in culture compared to Birabresib (OTX015) treatment alone (PMID: 32927276).||32927276|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|